PhaseBio begins Phase I hypertension study with Vasomera

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Big Data Integration Transforming Clinical Trials

In the years that have gone by, the big...

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

Asia’s CROs VCs: Blurring Service Provider & Investor Roles

In a time characterized by accelerated innovation and ever-more...

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

PhaseBio Pharmaceuticals, a biotechnology company, has initiated Phase I clinical study with its novel compound, Vasomera (PB1046), in patients with Stage 1 and 2 essential hypertension.

The primary objective of the placebo-controlled study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic profile of single ascending doses of Vasomera administered subcutaneously to patients with essential hypertension. The double-blind trial is being conducted in the US and is expected to be completed by the end of 2012.

Vasomera is a VPAC2-selective Vasoactive Intestinal Peptide (VIP) agonist which has been genetically engineered using the company’s elastin-like biopolymer (ELP) technology.

PhaseBio executive chairman and chief scientific officer Craig Rosen said Vasomera further validates the broad applicability of ELP technology to develop highly differentiated and improved biotherapeutic drugs for significant unmet medical needs.

 

Latest stories

Related stories

Big Data Integration Transforming Clinical Trials

In the years that have gone by, the big...

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

Asia’s CROs VCs: Blurring Service Provider & Investor Roles

In a time characterized by accelerated innovation and ever-more...

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back